Feras Alsulaiman

Dr. Feras Alsulaiman

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in American Journal of Case Reports
Verified
Journal Article
Open access
AAAli Alhashim
Ali Alhashim
KHKawther Hadhiah
Kawther Hadhiah
ZKZahra Al Khalifah
Zahra Al Khalifah
FAFatimah Mohammed Alhaddad
Fatimah Mohammed Alhaddad
SASara A. Al Arhain
Sara A. Al Arhain
MAMustafa AlQarni
Mustafa AlQarni
Unusual clinical course COVID-19 is an acute respiratory disease caused by the SARS-CoV-2 virus, which was discovered in 2019. The high transmission and seriousness of COVID-19 necessitated the development of an effective vaccine to control spread of the disease. Multiple vaccines have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration, namely, the Pfizer-BioNTech, Moderna (mRNA), and the Johnson & Johnson/Janssen (vector) vaccines. As these novel vaccines have been used, adverse effects have been reported, ranging from mild myalgia to severe anaphylaxis and thrombotic events. Thrombotic consequences raised suspicion for the development of cerebral venous sinus thrombosis (CVST), which is a severe condition associated with occlusion of venous sinuses and disruption of the venous system flow. A 28-year-old healthy woman presented with a 2-week history of persistent and progressive headache 4 days after receiving an mRNA COVID-19 vaccine (Pfizer-BioNTech). Cerebral computed tomography (CT) and CT venography confirmed the presence of extensive thrombus involving the left transverse and sigmoid sinus as well as the internal jugular vein. Furthermore, other than recent the COVID-19 vaccination, there were no precipitant risk factors in her clinical history or in the detailed laboratory work-up. Headache associated with red flags following administration of any COVID-19 vaccine should prompt urgent neuroimaging to rule out secondary causes and determine the appropriate management. Our patient lacked the typical profile of CVST commonly seen following administration of the Oxford-Astrazeneca vaccine. The findings of low platelet count may indicate the peculiar pathophysiology of a thrombotic event associated with with the Pfizer vaccine.

1 February 2021 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
FAFahd Alkhamis
Fahd Alkhamis
KAKhalid Alhajri
Khalid Alhajri
DADanah Aljaafari
Danah Aljaafari
AAAli Alhashim
Ali Alhashim
AAAdnan Alsamarah
Adnan Alsamarah
MAMajed AlAbdali
Majed AlAbdali
Background: A high mega jugular Bulb is an enlarged and swollen upper portion of the internal jugular vein with a variation of its anatomical position among the population, mostly situated below the hypotympanum. Although most cases of jugular bulb diverticulum are asymptomatic, excessive pressure on the surrounding structures might cause various symptoms, most prominently vertigo, sensorineural hearing loss, or tinnitus. Case Report: A middle-aged male who was referred to the Department of Neurology with a recurrent complaint of left-sided facial weakness associated with headache and vertigo for a period of 24 months. His symptoms were episodic, furthermore exacerbated by visiting high altitude sites. Non-resolving with conventional medical treatment. After thorough investigation, including preoperative and postoperative audiograms, neuroimaging, including computed tomography as well as magnetic resonance angiography, he was diagnosed to have right-sided superior mega jugular bulb as a causative factor. After surgical management, the patient improved significantly. At his regular follow-up in our clinic there were no exacerbations of his symptoms. Conclusion: Among patients who present with recurrent non-resolving facial palsy in which no apparent causative factor is identified, high jugular bulb should be suspected and investigated. Comprehensive and detailed medical history is essential for raising the suspicion for the diagnosis. Such as the case presented eliciting high altitudes as the main precipitating factor. The diagnosis is clinically elusive, commonly obscured by other common diagnoses. Surgery is recommended if antihypertensive drugs do not show improvement.

1 June 2025 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
OAOmer Alsulaiman
Omer Alsulaiman
AAAhmed Alsaati
Ahmed Alsaati
FAFeras Alsulaiman
Feras Alsulaiman
DADanah Aljaafari
Danah Aljaafari
MAMajed Alabdali
Majed Alabdali
Herpes zoster infection, commonly known as shingles, typically involves the thoracic and lumbar dermatomes. Sacral involvement is rare, occurring in only 4– 8% of cases. This report presents a 55-year-old female with herpes zoster affecting the S1 dermatome, manifesting as burning pain and clustered vesicles on her right leg, without motor dysfunction or urinary symptoms. A clinical diagnosis was made based on a characteristic unilateral S1 dermatomal vesicular eruption. Despite the rarity of sacral herpes zoster without motor involvement, the patient responded well to antiviral treatment and neuropathic pain management, with no complications noted in the long-term follow-up. This case highlights the necessity for clinicians to consider sacral herpes zoster in patients with radicular pain to prevent misdiagnosis.

1 May 2021 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
DADanah Aljaafari
Danah Aljaafari
SASalam Almustafa
Salam Almustafa
AAAbdulrahman Saleh Ali
Abdulrahman Saleh Ali
HAHosam Aldalbahi
Hosam Aldalbahi
NANorah Ibrahim Albahli
Norah Ibrahim Albahli
MAMajed Alabdali
Majed Alabdali
Background: Miller Fisher syndrome (MFS), a triad of ophthalmoplegia, areflexia and ataxia, is one of the regional variants of Guillain-Barré syndrome (GBS) that might account for a quarter of all cases of GBS, especially in Asian countries. There is history of an antecedent upper respiratory tract infection in up to two thirds of MFS cases. However, association of MFS in adults and pneumonia is rarely reported and in those cases causative pathogen was Mycoplasma pneumoniae. To our knowledge, association of MFS and ventilator-associated pneumonia has never been reported. So, we hereby report the first case of MFS which followed ventilator-associated pneumonia (VAP). Case Report: We report case of a 22-year-old male who was known to have temporal lobe epilepsy and mental retardation. He presented with status epilepticus. He was sedated and put on mechanical ventilation. Two days later, he developed a fever associated with increased tracheobronchial secretions and new infiltrates on chest X-ray. Diagnosis of VAP was made. Upon improvement, he was extubated and shifted out of ICU. Ten days after the onset of fever, he developed gradual onset bulbar weakness and ataxia. On examination, he had generalized areflexia and ataxia. CSF analysis showed cytoalbuminic dissociation. Antibodies against ganglioside complex were elevated. Diagnosis of sero-negative MFS was made, and intravenous immunoglobulin (IVIG) was started. He improved remarkably within two days. Conclusion: MFS is immune-mediated entity which is usually triggered by upper respiratory tract infection but in rare cases it can be consequence of pneumonia including VAP. Further research is needed to establish link between MFS and VAP.

27 February 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ESErum Shariff
Erum Shariff
SNsaima Nazish
saima Nazish
RSRizwana Shahid
Rizwana Shahid
AZAzra Zafar
Azra Zafar
ZYZakia M. Yasawy
Zakia M. Yasawy
MAMajed AlAbdali
Majed AlAbdali

6 February 2024 in Clinical Eeg and Neuroscience
Verified
Journal Article
Closed access
ESErum Shariff
Erum Shariff
SNSaima Nazish
Saima Nazish
AZAzra Zafar
Azra Zafar
RSRizwana Shahid
Rizwana Shahid
NANorah A. ALKhaldi
Norah A. ALKhaldi
MAMajed Alabdali
Majed Alabdali
Objective: Post-stroke seizures (PSS) are one of the major stroke-related complications. Early therapeutic interventions are critical therefore using electroencephalography (EEG) as a predictive tool for future recurrence may be helpful. We aimed to assess frequencies of different EEG patterns in patients with PSS and their association with seizure recurrence and functional outcomes. Methods: All patients admitted with PSS were included and underwent interictal EEG recording during their admission and monitored for seizure recurrence for 24 months. Results: PSS was reported in 106 patients. Generalized slow wave activity (GSWA) was the most frequent EEG pattern observed (n = 62, 58.5%), followed by Focal sharp wave discharges (FSWDs) (n = 57, 55.8%), focal slow wave activity (FSWA) (n = 56, 52.8%), periodic discharges (PDs) (n = 13, 12.3%), and ictal epileptiform abnormalities (n = 6, 5.7%). FSWA and ictal EAs were positively associated with seizure recurrence ( p < .001 and p = .015 respectively) and it remained significant even after adjusting for age, sex, stroke severity, stroke subtype, or use of anti-seizure medications (ASMs). Other positive associations were status epilepticus (SE) ( p = .015), and use of older ASM ( p < .001). FSWA and GSWA in EEG were positively associated with severe functional disability ( p = .055, p = .015 respectively). Other associations were; Diabetes Mellitus ( p = .034), Chronic Kidney Disease ( p = .002), use of older ASMs ( p = .037), presence of late PSS ( p = .021), and those with Ischemic stroke ( p = .010). Conclusions: Recognition and documentation of PSS-related EEG characteristics are important, as certain EEG patterns may help to identify the patients who are at risk of developing recurrence or worse functional outcomes.